Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29038034 | 1.00 | ZDHHC7 (0.48) | ZDHHC7MMESMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL1415280 | 0.87 | ZDHHC7 (0.54) | ZDHHC7MMESMN1; SMN2CA14CA12 | |
| SCHEMBL6683720 | 0.86 | ZDHHC7 (0.48) | ZDHHC7MMESMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL106430 | 0.84 | ZDHHC7 (0.47) | ZDHHC7MMESMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL22162842 | 0.82 | ZDHHC7 (0.46) | ZDHHC7MMESMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL22162843 | 0.82 | ZDHHC7 (0.46) | ZDHHC7MMESMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL19998323 | 0.80 | ZDHHC7 (0.41) | ZDHHC7MMETAS1R3TAS1R1BIRC2 | |
| SCHEMBL30520135 | 0.79 | ALDH1A1 (0.40) | ZDHHC7SMN1; SMN2POLBRNPEP | |
| SCHEMBL1370661 | 0.79 | ALDH1A1 (0.40) | ZDHHC7SMN1; SMN2POLBRNPEP | |
| SCHEMBL27575981 | 0.79 | ZDHHC7 (0.47) | ZDHHC7MMESMN1; SMN2CA14FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250084044-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4462999-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | Enko Chem, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118541030-A | Protoporphyrinogen oxidase inhibitors | 恩科化学公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2023137307-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-116425682-A | Pyrimidine-1 (2H) -oxo compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-4945092-A | Substituted 1-(oxopyrrolidinylalkanoyl)-piperazines useful as nootropics | CIBA-GEIGY CORPORATION (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0185380-B1 | THIOL BASED COLLAGENASE INHIBITORS | G.D. Searle & Co. (US) | 1990-04-11 | — | — | EP | disclosed |
| US-4681966-A | ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0185380-A2 | Thiol based collagenase inhibitors | G.D. Searle & Co. (US) | 1986-06-25 | — | — | EP | disclosed |
| US-4595700-A | Thiol based collagenase inhibitors | G. D. SEARLE & CO. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4593098-A | Piperazinone and piperazine polypeptides | THE UPJOHN COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4534897-A | Piperazinone, piperazine, 1,4-diazepin-2-one and 1,4-diazepine intermediate compounds | THE UPJOHN COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| US-4251438-A | ANALGESICS, PSYCHOTHERAPEUTIC AGENTS | THE UPJOHN COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-4234744-A | Process for the production of aminoacid hydrochlorides/or diaminoacid dihydrochlorides | DEUTSCHE GOLD- UND SILBER SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-11-18 | — | — | US | disclosed |
| US-3996940-A | Tobacco product | R. J. REYNOLDS TOBACCO COMPANY (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084044-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | PPOX, CYP4X1, PNPO | ZDHHC7 2447/4885MME 3379/4885SMN1; SMN2 4863/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | ZDHHC7 734/4885MME 1380/4885SMN1; SMN2 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.